Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
Recruiting · NCT07741448 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC | renal pelvis/ureter urothelial carcinoma | Recruiting | Phase 2 | 2026-08-03 | NCT07741448 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhiquan Hu | 2 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog | Wuhan | China | 1 |
| Huanggang Central Hospital | Huanggang | China | 4 |
| Hubei Cancer Hospital | Wuhan | China | 95 |
| Jingzhou Central Hospital | Jingzhou | China | 14 |
| Renmin Hospital of Wuhan University | Wuhan | China | 42 |
| Taihe Hospital | Shiyan | China | 6 |
| The Central Hospital of Wuhan | Wuhan | China | 9 |
| Xiangyang Central Hospital | Xiangyang | China | 17 |
| Yichang Central People's Hospital | Yichang | China | 17 |
| Zhongnan Hospital of Wuhan University | Wuhan | China | 65 |